drugset / Trial / NCT01466465

Vitamin D and Grass Pollen Specific Immunotherapy

NCT01466465

Phase 2 Completed 35 enrolled Charite University, Berlin, Germany
RandomizedParallel-groupDouble-blindTreatment

Summary

Allergen-specific immunotherapy is the only causal therapy of Immunoglobulin E-induced allergies like allergic rhinoconjunctivitis. Despite progress during the last decades it is limited by a long treatment time and high non-responder frequency. Based on experimental and epidemiological evidences we hypothesize that vitamin D can act as an effective immunomodulatory adjuvant to overcome these limitations.

Timeline

Start
2011-10
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified Oral

Indications